Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA integrity contract terminated

Executive Summary

FDA Oct. 4 "Talk Paper" notes that agency has terminated contract with D.C. law firm Shaw, Pittman, Potts & Trowbridge, which had been hired to review integrity of FDA's product review systems. FDA's decision to end the contract follows criticism of the arrangement by Rep. Dingell (D-Mich.) at a Sept. 12 hearing of his House Oversight/Investigations Subcommittee ("The Pink Sheet" Sept. 16, p. 9). Dingell's concern stemmed from comments made by a partner at Shaw, Pittman in an issue of Legal Times that implied the firm would use its experience at FDA to gain new business opportunities. "FDA believes that the need to counter these charges would make fulfillment of the contract more difficult, and the agency made the decision to terminate it at this time," FDA said. The contract for $ 710,558 was signed on July 10 and the firm's report was due on Jan. 9. FDA is not going to hire a replacement. . . .
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS019834

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel